Source:
MD Anderson Cancer Center
Technology:
Treating neurodegeneration and neuronal injuries through the development of novel therapeutics that can prevent neuronal cell death.
Series A:
$31M
Investment Date:
Q3 2018
Development of novel therapeutics in treating neurodegeneration and neuronal injuries.
Technology:
To develop new medical countermeasure for nerve agent exposure
Focused on developing therapies for those fighting to overcome addiction.
Source:
Case Western Reserve University, University of Texas Southwestern Medical Center
Technology:
First-in-class therapies for enhancing tissue repair and regeneration
Series A:
$5.9M
Investment Date:
Q3 2017
First-in-class therapies for enhancing tissue repair and regeneration
Acquired by Amgen Inc.
Source:
University of Minnesota
Technology:
Oncology: A new class of therapies to break drug resistance in cancer
Series A:
$7M
Investment Date:
Q4 2016
A new class of therapies to break drug resistance in cancer
Source:
The Rockefeller University
Technology:
New generation of natural product derived therapeutics for human disease.
Series A:
$20M
Investment Date:
Q1 2016
New generation of natural product derived therapeutics for human disease.
Source:
Weill Cornell Medicine
Technology:
Novel approach to therapeutics for cancer and metabolic diseases.
Series A:
$48M
Investment Date:
Q1 2016
Graduation Date:
Q3 2017
Novel approach to therapeutics for cancer and metabolic diseases.
Acquired by global pharmaceutical company
Accelerating Success
From start-up to standout.
We provide start-ups with a structured and comprehensive toolkit for development, milestone achievement and eventual autonomy. Take a look at a few of the success stories from our growing portfolio of diverse and exciting companies.
